as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹34.29
Change
+0.06 (0.18%)
Open
₹34.9
Prev. Close
₹34.23
Day High
₹35.99
Day Low
₹33.76
Volume Analysis
Traded
891,671
Delivered
639,307
Delivery %
71.7%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Promoter holding is rising
Weaknesses (1)
- •Low return on equity (8.91%)
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹37.83 | ₹36.91 | ₹35.6 | ₹34.68 | ₹33.37 | ₹32.45 | ₹31.14 |
| Fibonacci | ₹36.91 | ₹36.06 | ₹35.53 | ₹34.68 | ₹33.83 | ₹33.3 | ₹32.45 |
| Camarilla | ₹34.9 | ₹34.7 | ₹34.49 | ₹34.68 | ₹34.09 | ₹33.88 | ₹33.68 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-17.21%
1 Week
+4.32%
1 Month
-3.24%
3 Months
-17.81%
6 Months
-16.71%
1 Year
-69.87%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹8.05
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
5.23%
Net margin 6.54% × asset turnover 0.46x × equity multiplier 1.74x
Company Overview
Sector
Healthcare
Market Cap
₹2,401 Cr
P/E (TTM)
98.1
ROE
8.91%
Book Value
₹5.88
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Fischer Medical Venture L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 51/100. The strongest factor is Financial Strength (100/100), while Momentum (4/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (8.91%). FII holding has been rising.
TopFund Score — Fundamentals Quality
51/100 — AverageData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Promoter holding has increased by 0.94% over last quarter.
- −Stock is trading at 5.84 times its book value
- −Company has a low return on equity of 5.74% over last 3 years.
- −Company has high debtors of 342 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Chairman’s letter reviews global expansion, new products, Vecura collaboration, and ₹59.67 crore promoter infill.
Newspaper Advertisement for completion of dispatch, of Annual Report FY 2025-26, to Shareholders
FY2025-26 Business Responsibility and Sustainability Report filed on September 7, 2026.
Submitted FY2025-26 annual report; AGM scheduled for September 29, 2026, via online/VC.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 21 | 10 | 40 | 12 | 49 | 23 | 86 | 101 | 98 | 82 |
| Expenses + | 0 | 18 | 10 | 39 | 11 | 47 | 19 | 70 | 80 | 101 | 71 |
| Operating Profit | 0 | 3 | 0 | 1 | 0 | 3 | 4 | 16 | 22 | -4 | 11 |
| OPM % | — | 12.07% | -2.08% | 1.26% | 3.15% | 5.1% | 17.02% | 18.79% | 21.34% | -3.87% | 13.73% |
| Other Income + | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 2 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 4 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 3 | 0 | 0 | 0 | 2 | 10 | 17 | 21 | -8 | 8 |
| Tax % | — | 6.18% | 271.43% | -38.1% | 350.0% | 26.04% | 51.55% | 19.46% | 9.18% | 64.03% | 51.6% |
| Net Profit + | 0 | 3 | 0 | 0 | 0 | 1 | 5 | 14 | 19 | -12 | 4 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales + | 0 | 21 | 111 | 308 | 367 |
| Expenses + | 0 | 19 | 107 | 265 | 322 |
| Operating Profit | 0 | 2 | 3 | 43 | 45 |
| OPM % | 11.0% | 9.0% | 3.0% | 14.0% | 12.0% |
| Other Income + | 0 | 0 | 1 | 12 | 6 |
| Interest | 0 | 0 | 0 | 6 | 9 |
| Depreciation | 0 | 0 | 2 | 3 | 4 |
| Profit before tax | 0 | 2 | 3 | 47 | 39 |
| Tax % | — | 13.0% | 37.0% | 33.0% | — |
| Net Profit + | 0 | 2 | 1 | 31 | 24 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 |
| Dividend Payout % | 0.0% | 0.0% | 22.0% | 1.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Reserves | 0 | 28 | 274 | 320 |
| Borrowings + | 1 | 2 | 85 | 107 |
| Other Liabilities + | 0 | 4 | 34 | 179 |
| Total Liabilities | 0 | 86 | 457 | 671 |
| Fixed Assets + | 0 | 15 | 24 | 32 |
| CWIP | 0 | 0 | 1 | 3 |
| Investments | 0 | 1 | 7 | 118 |
| Other Assets + | 0 | 70 | 425 | 519 |
| Total Assets | 0 | 86 | 457 | 671 |
| Equity Capital | 0 | 54 | 64 | 65 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | — | -7 | -86 | -101 |
| Cash from Investing Activity + | — | -29 | -125 | -5 |
| Cash from Financing Activity + | — | 37 | 315 | 14 |
| Net Cash Flow | — | 1 | 103 | -92 |
| CFO/OP | — | -392 | -2,555 | -194 |
| Free Cash Flow | — | -8 | -91 | 6 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 99.99% | 93.24% | 18.33% | 18.33% | 18.32% | 30.51% | 31.23% | 31.22% | 31.99% | 31.51% | 31.01% | 30.09% |
| Promoters | 0.0% | 0.0% | 74.91% | 74.91% | 74.91% | 62.82% | 61.8% | 61.8% | 61.8% | 62.15% | 62.15% | 63.09% |
| FII | 0.0% | 5.07% | 5.07% | 5.07% | 5.07% | 5.23% | 5.55% | 5.57% | 4.85% | 4.97% | 5.48% | 5.57% |
| DII | 0.0% | 1.68% | 1.68% | 1.68% | 1.68% | 1.44% | 1.42% | 1.42% | 1.36% | 1.38% | 1.35% | 1.26% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Fischer Medical Venture L (this stock) | 2,401 | 98.1 | 5.85 | 8.91% |
| Beta Drugs Limited | 2,400 | 52.6 | 8.98 | 18.8% |
| Shukra Pharmaceuticals L | 2,465 | 72.6 | 27.27 | 28.9% |
| Indoco Remedies Ltd. | 2,306 | — | 2.45 | -9.36% |
| Fredun Pharmaceuticals L | 2,305 | 52.6 | 8.2 | 15.6% |
| Panacea Biotec Ltd | 2,282 | — | 2.74 | -2.42% |
| Sakar Healthcare Limited | 2,527 | 70.0 | 7.78 | 9.99% |
Which Mutual Funds Hold Fischer Medical Venture L?
Frequently Asked Questions about Fischer Medical Venture L
Fischer Medical Venture L (FISCHER) closed at ₹34.29 on NSE on 25 September 2026, up 0.06 (0.18%) from the previous close.
Fischer Medical Venture L trades on the NSE (National Stock Exchange of India) under the symbol FISCHER.
Fischer Medical Venture L has a trailing twelve-month P/E (price-to-earnings) ratio of 98.1.
Fischer Medical Venture L has a dividend yield of 0.15%.
Fischer Medical Venture L's 52-week high is ₹122.0 and its 52-week low is ₹31.0.
Fischer Medical Venture L has a market capitalisation of ₹2,401 crore.
Fischer Medical Venture L has a TopFund Quality Score of 51/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Fischer Medical Venture L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.